August 26, 2021
During this meeting, TBDWG members will focus on plans to develop the next report due December 2022 on federal tick-borne activities and research, taking into consideration the 2018 and 2020 reports.
Public Comment – Information and Instructions
The public will have an opportunity to present their views to the TBDWG during the meeting’s public comment session or by submitting their views in writing. Comments should be pertinent to the meeting discussion.
Verbal Public Comment:
Verbal remarks will be provided by the public over the phone during the live webcast and become part of the archived recording and meeting summary posted on this website.
Date and time: Thursday, August 26 (Exact time forthcoming)
To sign-up for verbal public comment:
- Submit an email request to email@example.com
- Use the email subject line: Verbal Public Comment – August 26
- Deadline: All sign-up requests must be received by 11:59 p.m., ET, Tuesday, August 17
Next steps: If more requests to provide verbal public comment are received than can be accommodated during this meeting, speakers will be randomly selected. You will receive notification on the status of your request on Monday, August 23.
- If you are selected to provide verbal public comment at the meeting, you will be asked to confirm that you are still available to speak during the assigned time. Upon confirmation, you will receive a call-in number and time to provide your comment. Each person will be limited to 3 minutes in order to accommodate as many speakers as possible. If you are no longer able to provide verbal public comment, HHS will randomly select another speaker.
- If you are not selected, you are welcome to submit your name for consideration in a future meeting of the Working Group once the meeting information is posted.
- Please note that after this meeting, preference will be given to individuals who have not provided verbal comments at a meeting of the 2022 Working Group.
Written Public Comment:
Written public comments are shared with Working Group members and posted on this webpage and made accessible to the public in advance of the meeting.
To submit a written public comment:
- Submit an email to firstname.lastname@example.org
- Use the email subject line: Written Public Comment – August 26
- Deadline: All written comments must be received by 11:59 p.m., ET, Tuesday, August 17
- Provide your preferred identification: Tell us how you prefer to be identified with your comment. We cannot post your comment without this information. You may choose one or more of the following options:
- Use your name
- Be listed as anonymous
- Include your city and/or state
- Provide comments on behalf of an organization (please include the organization’s full name)
Writing your public comment:
- Format: Comments must be in the body of your email or in an attached Word document.
- Page Limit: Comments must not exceed four (4) pages in Calibri or Times New Roman, 11 point font (text that exceeds four pages will be deleted).
- Graphics: Do not include graphics, images, text boxes, or tables. If included, they will not be retained.
- Links: Hyperlinks will only be added for “.gov” sites (local, state, or federal). For all other reference sites, please insert the full URL (e.g., http://learn.genetics.utah.edu/content/epigenetics).
- Attachments: Do not include any attachments. We are also unable to include attachments as supporting documentation to written comments.
Next steps: Your written comment will be posted to this website before the meeting. If you have any questions or concerns about submitting your comment, contact us at email@example.com
It is my strong opinion that the Lyme/MSIDS community will only move forward by doing the work ourselves, independently from the government and institutions/researchers that own patents on products relating to tick-borne illness. We have tried working with the government for over 40 years with no measurable positive results. Productive help has only occurred by independent researchers and ILADS trained doctors who are clinically treating patients.
I DO NOT SUPPORT OR PROMOTE ANY MORE LYME/MSIDS/TICK RESEARCH FUNDING TO THE NIH/CDC/NIAID/IDSA WHO HAVE ONLY REPEATEDLY PROVEN THEY ARE AGAINST PATIENTS.